Pirtobrutinib - HY-131328
Nur noch %1 verfügbar
Catalog #
HY-131328
Ab
93,00 €
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-131328/Pirtobrutinib-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | Cancer-Kinase/protease |
| Alternative Names | LOXO-305 |
| CAS | 2101700-15-4 |
| Storage | 4°C (Powder, stored under nitrogen) |
| MWT | 479.43 |
| Solubility | DMSO : 50 mg/mL (ultrasonic) |
| Clinical Information | Launched |
| Target | Btk |
| Application: | Cancer-Kinase/protease |
|---|